texas oncology more breakthroughs. more victories
We’re experiencing severe weather in the state of Texas. Some of our cancer centers are delayed opening or are closed. View More Important Notifications x
Request an Appointment

Austin Clinical Trials

Texas Oncology participates in a wide range of cancer research and clinical trials in the Austin area paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in Austin, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks of Participating in Clinical Trials

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Clinical Trial Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the Austin area and talk to you doctor to determine which clinical trial is right for you.

The Benefits and Risks to Consider in Clinical Trials 

Dr. Jason Melear of Texas Oncology–Austin Midtown explains the important benefits and potential risks for patients to consider when deciding to participate in a clinical trial. Learn More.

Biliary Cancer

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Round Rock

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Brain Cancer

Title: Ph2 study of BPM31510 in newly diagnosed GB View

Description: A Phase 2 study of BPM31510 with Vitamin K1 in subjects with newly diagnosed glioblastoma (GB) (BPM31510IV-11)

Indication: Brain Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 study of BPM31510 in newly diagnosed GB View

Description: A Phase 2 study of BPM31510 with Vitamin K1 in subjects with newly diagnosed glioblastoma (GB) (BPM31510IV-11)

Indication: Brain Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Breast Cancer

Title: Retrospective analysis of adherence and patient reported outcomes for ribociclib (ribo) patients using ReX Technology Platform

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Title: Retrospective analysis of adherence and patient reported outcomes for ribociclib (ribo) patients using ReX Technology Platform

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Title: Retrospective analysis of adherence and patient reported outcomes for ribociclib (ribo) patients using ReX Technology Platform

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Title: Retrospective analysis of adherence and patient reported outcomes for ribociclib (ribo) patients using ReX Technology Platform

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD) View

Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD) View

Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD) View

Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD) View

Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Cervical Cancer

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III

Colon Cancer

Title: Ph1b AMG 510 MVASI Combo KRAS CRC View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with MVASI® and FOLFIRI and in Combination with MVASI® and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol M)

Indication: Colon Cancer

Location: Texas Oncology-Austin Midtown

Phase: I

Title: Ph1b AMG 510 MVASI Combo KRAS CRC View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with MVASI® and FOLFIRI and in Combination with MVASI® and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol M)

Indication: Colon Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Colon Cancer

Location: Texas Oncology-Austin Central

Phase: II/III

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Colon Cancer

Location: Texas Oncology-South Austin

Phase: II/III

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Colon Cancer

Location: Texas Oncology-Austin Midtown

Phase: II/III

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Colon Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Austin Midtown

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II/III

Endometrial Cancer

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Austin Central

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-South Austin

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Fallopian Tube Cancer

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III

Head and Neck Cancer

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Head and Neck Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Round Rock

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Leukemia

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Austin Central

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-South Austin

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Round Rock

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Austin Midtown

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Liver Cancer

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Austin Midtown

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I

Lung Cancer

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician’s Choice of Immune Checkpoint Inhibitor Compared with Docetaxel in Patients with Non-Small-Cell Lung Cancer after First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance (VIRO-25 Study) - Olvi-Vec- NSCLC-025

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician’s Choice of Immune Checkpoint Inhibitor Compared with Docetaxel in Patients with Non-Small-Cell Lung Cancer after First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance (VIRO-25 Study) - Olvi-Vec- NSCLC-025

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II/III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Round Rock

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Round Rock

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph2 Platform Substudy-01: patients w/ no prior systemic treatment for metastatic NSCLC View

Description: A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic NSCLC (GS-US-624-6376-01)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph2 Platform Substudy-01: patients w/ no prior systemic treatment for metastatic NSCLC View

Description: A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic NSCLC (GS-US-624-6376-01)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: Ph2 Platform Substudy-01: patients w/ no prior systemic treatment for metastatic NSCLC View

Description: A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic NSCLC (GS-US-624-6376-01)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 Platform Substudy-01: patients w/ no prior systemic treatment for metastatic NSCLC View

Description: A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic NSCLC (GS-US-624-6376-01)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Round Rock

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC View

Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC View

Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC View

Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC View

Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 SGN-B6A vs docetaxel NSCLC View

Description: A randomized phase 3 open-label study to evaluate sigvotatug vedotin compared with docetaxel in adult participants with previously treated non-small cell lung cancer (Be6A Lung-01)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 SGN-B6A vs docetaxel NSCLC View

Description: A randomized phase 3 open-label study to evaluate sigvotatug vedotin compared with docetaxel in adult participants with previously treated non-small cell lung cancer (Be6A Lung-01)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 SGN-B6A vs docetaxel NSCLC View

Description: A randomized phase 3 open-label study to evaluate sigvotatug vedotin compared with docetaxel in adult participants with previously treated non-small cell lung cancer (Be6A Lung-01)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 SGN-B6A vs docetaxel NSCLC View

Description: A randomized phase 3 open-label study to evaluate sigvotatug vedotin compared with docetaxel in adult participants with previously treated non-small cell lung cancer (Be6A Lung-01)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Lymphomas

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Austin Central

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-South Austin

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Round Rock

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Austin Midtown

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Austin Central

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-South Austin

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Austin Midtown

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-South Austin

Phase: II

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Lymphomas

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Lymphomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-South Austin

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Melanoma

Title: Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2 View

Description: A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02)

Indication: Melanoma

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2 View

Description: A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02)

Indication: Melanoma

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Miscellanous

Title: Phase 1 Open-Label Study to Evaluate Safety and Determine the Maximum Tolerated Dose Of IBRX-042 In Subjects With HPV-Associated Tumors

Indication: Miscellanous

Location: Texas Oncology-Austin Midtown

Phase: I

Title: Phase 1 Open-Label Study to Evaluate Safety and Determine the Maximum Tolerated Dose Of IBRX-042 In Subjects With HPV-Associated Tumors

Indication: Miscellanous

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I

Myelomas

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Austin Central

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-South Austin

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Austin Midtown

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Ovarian Cancer

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin Central

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-South Austin

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III

Title: Ph3 HIPEC with Cisplatin versus no HIPEC of Hyperthermic Ovarian Treatment Trial (HOTT) View

Description: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 HIPEC with Cisplatin versus no HIPEC of Hyperthermic Ovarian Treatment Trial (HOTT) View

Description: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)

Indication: Ovarian Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 HIPEC with Cisplatin versus no HIPEC of Hyperthermic Ovarian Treatment Trial (HOTT) View

Description: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: Ph3 HIPEC with Cisplatin versus no HIPEC of Hyperthermic Ovarian Treatment Trial (HOTT) View

Description: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: Ph3 HIPEC with Cisplatin versus no HIPEC of Hyperthermic Ovarian Treatment Trial (HOTT) View

Description: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III

Peritoneal Cancer

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III

Prostate Cancer

Title: Ph2 XmAB20717 GYN malig & CRPC View

Description: A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer (XmAb20717-05)

Indication: Prostate Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph2 XmAB20717 GYN malig & CRPC View

Description: A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer (XmAb20717-05)

Indication: Prostate Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: Ph2 XmAB20717 GYN malig & CRPC View

Description: A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer (XmAb20717-05)

Indication: Prostate Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 XmAB20717 GYN malig & CRPC View

Description: A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer (XmAb20717-05)

Indication: Prostate Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Rectal Cancer

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Austin Midtown

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II/III

Renal Cancer

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Austin Midtown

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I

Solid Tumors

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Central

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-South Austin

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-South Austin

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and Chemotherapy in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: I

Title: Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and Chemotherapy in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin Central

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-South Austin

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Central

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-South Austin

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Central

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-South Austin

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Texas Oncology-Austin Brain Tumor Center

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Title: Retrospective analysis of adherence and patient reported outcomes for ribociclib (ribo) patients using ReX Technology Platform

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Title: Phase 1 Open-Label Study to Evaluate Safety and Determine the Maximum Tolerated Dose Of IBRX-042 In Subjects With HPV-Associated Tumors

Indication: Miscellanous

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph2 study of BPM31510 in newly diagnosed GB View

Description: A Phase 2 study of BPM31510 with Vitamin K1 in subjects with newly diagnosed glioblastoma (GB) (BPM31510IV-11)

Indication: Brain Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD) View

Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph1b AMG 510 MVASI Combo KRAS CRC View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with MVASI® and FOLFIRI and in Combination with MVASI® and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol M)

Indication: Colon Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Colon Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II/III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II/III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph2 Platform Substudy-01: patients w/ no prior systemic treatment for metastatic NSCLC View

Description: A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic NSCLC (GS-US-624-6376-01)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC View

Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 SGN-B6A vs docetaxel NSCLC View

Description: A randomized phase 3 open-label study to evaluate sigvotatug vedotin compared with docetaxel in adult participants with previously treated non-small cell lung cancer (Be6A Lung-01)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Lymphomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2 View

Description: A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02)

Indication: Melanoma

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: Ph2 XmAB20717 GYN malig & CRPC View

Description: A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer (XmAb20717-05)

Indication: Prostate Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II/III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and Chemotherapy in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Texas Oncology-Austin Central

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Title: Retrospective analysis of adherence and patient reported outcomes for ribociclib (ribo) patients using ReX Technology Platform

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician’s Choice of Immune Checkpoint Inhibitor Compared with Docetaxel in Patients with Non-Small-Cell Lung Cancer after First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance (VIRO-25 Study) - Olvi-Vec- NSCLC-025

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD) View

Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Colon Cancer

Location: Texas Oncology-Austin Central

Phase: II/III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Austin Central

Phase: I/II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: II/III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: I/II

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph2 Platform Substudy-01: patients w/ no prior systemic treatment for metastatic NSCLC View

Description: A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic NSCLC (GS-US-624-6376-01)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC View

Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 SGN-B6A vs docetaxel NSCLC View

Description: A randomized phase 3 open-label study to evaluate sigvotatug vedotin compared with docetaxel in adult participants with previously treated non-small cell lung cancer (Be6A Lung-01)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Austin Central

Phase: I

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Austin Central

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Austin Central

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin Central

Phase: I/II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 HIPEC with Cisplatin versus no HIPEC of Hyperthermic Ovarian Treatment Trial (HOTT) View

Description: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph2 XmAB20717 GYN malig & CRPC View

Description: A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer (XmAb20717-05)

Indication: Prostate Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Central

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Austin Central

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin Central

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Central

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Central

Phase: I/II

Texas Oncology-Austin Midtown

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Title: Retrospective analysis of adherence and patient reported outcomes for ribociclib (ribo) patients using ReX Technology Platform

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Title: Phase 1 Open-Label Study to Evaluate Safety and Determine the Maximum Tolerated Dose Of IBRX-042 In Subjects With HPV-Associated Tumors

Indication: Miscellanous

Location: Texas Oncology-Austin Midtown

Phase: I

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 study of BPM31510 in newly diagnosed GB View

Description: A Phase 2 study of BPM31510 with Vitamin K1 in subjects with newly diagnosed glioblastoma (GB) (BPM31510IV-11)

Indication: Brain Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD) View

Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph1b AMG 510 MVASI Combo KRAS CRC View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with MVASI® and FOLFIRI and in Combination with MVASI® and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol M)

Indication: Colon Cancer

Location: Texas Oncology-Austin Midtown

Phase: I

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Colon Cancer

Location: Texas Oncology-Austin Midtown

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Austin Midtown

Phase: II/III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Austin Midtown

Phase: I

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: II/III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph2 Platform Substudy-01: patients w/ no prior systemic treatment for metastatic NSCLC View

Description: A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic NSCLC (GS-US-624-6376-01)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC View

Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 SGN-B6A vs docetaxel NSCLC View

Description: A randomized phase 3 open-label study to evaluate sigvotatug vedotin compared with docetaxel in adult participants with previously treated non-small cell lung cancer (Be6A Lung-01)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Austin Midtown

Phase: I

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Lymphomas

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2 View

Description: A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02)

Indication: Melanoma

Location: Texas Oncology-Austin Midtown

Phase: III

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Austin Midtown

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: Ph2 XmAB20717 GYN malig & CRPC View

Description: A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer (XmAb20717-05)

Indication: Prostate Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Austin Midtown

Phase: II/III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Austin Midtown

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and Chemotherapy in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: I

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: I/II

Texas Oncology-Austin North Next Oncology

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III

Title: Ph3 HIPEC with Cisplatin versus no HIPEC of Hyperthermic Ovarian Treatment Trial (HOTT) View

Description: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Texas Oncology-Austin North Suite 120

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: Ph3 HIPEC with Cisplatin versus no HIPEC of Hyperthermic Ovarian Treatment Trial (HOTT) View

Description: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Texas Oncology-Austin North Suite 300

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: Ph3 HIPEC with Cisplatin versus no HIPEC of Hyperthermic Ovarian Treatment Trial (HOTT) View

Description: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Texas Oncology-Round Rock

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Round Rock

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Round Rock

Phase: III

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Round Rock

Phase: II

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Round Rock

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Round Rock

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Round Rock

Phase: III

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Round Rock

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Round Rock

Phase: I/II

Texas Oncology-South Austin

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Title: Retrospective analysis of adherence and patient reported outcomes for ribociclib (ribo) patients using ReX Technology Platform

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician’s Choice of Immune Checkpoint Inhibitor Compared with Docetaxel in Patients with Non-Small-Cell Lung Cancer after First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance (VIRO-25 Study) - Olvi-Vec- NSCLC-025

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD) View

Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Colon Cancer

Location: Texas Oncology-South Austin

Phase: II/III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-South Austin

Phase: I/II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Head and Neck Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-South Austin

Phase: II

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: II/III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: I/II

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph2 Platform Substudy-01: patients w/ no prior systemic treatment for metastatic NSCLC View

Description: A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic NSCLC (GS-US-624-6376-01)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC View

Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 SGN-B6A vs docetaxel NSCLC View

Description: A randomized phase 3 open-label study to evaluate sigvotatug vedotin compared with docetaxel in adult participants with previously treated non-small cell lung cancer (Be6A Lung-01)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-South Austin

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-South Austin

Phase: I

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-South Austin

Phase: II

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-South Austin

Phase: III

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-South Austin

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-South Austin

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-South Austin

Phase: I/II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 HIPEC with Cisplatin versus no HIPEC of Hyperthermic Ovarian Treatment Trial (HOTT) View

Description: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)

Indication: Ovarian Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph2 XmAB20717 GYN malig & CRPC View

Description: A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer (XmAb20717-05)

Indication: Prostate Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-South Austin

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-South Austin

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-South Austin

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-South Austin

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-South Austin

Phase: I/II

No Phase

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Title: Retrospective analysis of adherence and patient reported outcomes for ribociclib (ribo) patients using ReX Technology Platform

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Title: Retrospective analysis of adherence and patient reported outcomes for ribociclib (ribo) patients using ReX Technology Platform

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Title: Retrospective analysis of adherence and patient reported outcomes for ribociclib (ribo) patients using ReX Technology Platform

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Title: Retrospective analysis of adherence and patient reported outcomes for ribociclib (ribo) patients using ReX Technology Platform

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase I

Title: Phase 1 Open-Label Study to Evaluate Safety and Determine the Maximum Tolerated Dose Of IBRX-042 In Subjects With HPV-Associated Tumors

Indication: Miscellanous

Location: Texas Oncology-Austin Midtown

Phase: I

Title: Phase 1 Open-Label Study to Evaluate Safety and Determine the Maximum Tolerated Dose Of IBRX-042 In Subjects With HPV-Associated Tumors

Indication: Miscellanous

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I

Title: Ph1b AMG 510 MVASI Combo KRAS CRC View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with MVASI® and FOLFIRI and in Combination with MVASI® and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol M)

Indication: Colon Cancer

Location: Texas Oncology-Austin Midtown

Phase: I

Title: Ph1b AMG 510 MVASI Combo KRAS CRC View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with MVASI® and FOLFIRI and in Combination with MVASI® and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol M)

Indication: Colon Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Austin Midtown

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Austin Central

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-South Austin

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Austin Midtown

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Austin Midtown

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I

Title: Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and Chemotherapy in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: I

Title: Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and Chemotherapy in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I

Phase I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Austin Central

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-South Austin

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Lymphomas

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Lymphomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin Central

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-South Austin

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Central

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-South Austin

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin Central

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-South Austin

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Central

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-South Austin

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advancedand/or Metastatic Solid Tumors GCT1184-01(PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Central

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-South Austin

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Suite 300

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Suite 120

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Austin North Next Oncology

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Round Rock

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: I/II

Phase II

Title: A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician’s Choice of Immune Checkpoint Inhibitor Compared with Docetaxel in Patients with Non-Small-Cell Lung Cancer after First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance (VIRO-25 Study) - Olvi-Vec- NSCLC-025

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician’s Choice of Immune Checkpoint Inhibitor Compared with Docetaxel in Patients with Non-Small-Cell Lung Cancer after First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance (VIRO-25 Study) - Olvi-Vec- NSCLC-025

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Round Rock

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph2 study of BPM31510 in newly diagnosed GB View

Description: A Phase 2 study of BPM31510 with Vitamin K1 in subjects with newly diagnosed glioblastoma (GB) (BPM31510IV-11)

Indication: Brain Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 study of BPM31510 in newly diagnosed GB View

Description: A Phase 2 study of BPM31510 with Vitamin K1 in subjects with newly diagnosed glioblastoma (GB) (BPM31510IV-11)

Indication: Brain Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Head and Neck Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Austin Central

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-South Austin

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Round Rock

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Austin Midtown

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph2 Platform Substudy-01: patients w/ no prior systemic treatment for metastatic NSCLC View

Description: A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic NSCLC (GS-US-624-6376-01)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph2 Platform Substudy-01: patients w/ no prior systemic treatment for metastatic NSCLC View

Description: A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic NSCLC (GS-US-624-6376-01)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: Ph2 Platform Substudy-01: patients w/ no prior systemic treatment for metastatic NSCLC View

Description: A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic NSCLC (GS-US-624-6376-01)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 Platform Substudy-01: patients w/ no prior systemic treatment for metastatic NSCLC View

Description: A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic NSCLC (GS-US-624-6376-01)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Austin Central

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-South Austin

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Round Rock

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Austin Midtown

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-South Austin

Phase: II

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-South Austin

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Austin Central

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-South Austin

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Austin Midtown

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010)

Indication: Myelomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph2 XmAB20717 GYN malig & CRPC View

Description: A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer (XmAb20717-05)

Indication: Prostate Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph2 XmAB20717 GYN malig & CRPC View

Description: A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer (XmAb20717-05)

Indication: Prostate Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: Ph2 XmAB20717 GYN malig & CRPC View

Description: A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer (XmAb20717-05)

Indication: Prostate Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 XmAB20717 GYN malig & CRPC View

Description: A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer (XmAb20717-05)

Indication: Prostate Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-South Austin

Phase: II

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 study of XmAb20717 in subjects with metCastration resistant prostate cancer View

Description: A Phase 2 Multiple-Dose Multiple-Arm Parallel Assignment Study to evaluate the Safety Tolerability and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer (XmAb20717-04)

Indication: Prostate Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Austin Central

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-South Austin

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Austin Midtown

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II

Phase II/III

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Colon Cancer

Location: Texas Oncology-Austin Central

Phase: II/III

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Colon Cancer

Location: Texas Oncology-South Austin

Phase: II/III

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Colon Cancer

Location: Texas Oncology-Austin Midtown

Phase: II/III

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Colon Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Austin Midtown

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Austin Midtown

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: II/III

Phase III

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD) View

Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD) View

Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD) View

Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD) View

Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Round Rock

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Round Rock

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Round Rock

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Round Rock

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC View

Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC View

Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC View

Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC View

Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 SGN-B6A vs docetaxel NSCLC View

Description: A randomized phase 3 open-label study to evaluate sigvotatug vedotin compared with docetaxel in adult participants with previously treated non-small cell lung cancer (Be6A Lung-01)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 SGN-B6A vs docetaxel NSCLC View

Description: A randomized phase 3 open-label study to evaluate sigvotatug vedotin compared with docetaxel in adult participants with previously treated non-small cell lung cancer (Be6A Lung-01)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 SGN-B6A vs docetaxel NSCLC View

Description: A randomized phase 3 open-label study to evaluate sigvotatug vedotin compared with docetaxel in adult participants with previously treated non-small cell lung cancer (Be6A Lung-01)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 SGN-B6A vs docetaxel NSCLC View

Description: A randomized phase 3 open-label study to evaluate sigvotatug vedotin compared with docetaxel in adult participants with previously treated non-small cell lung cancer (Be6A Lung-01)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2 View

Description: A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02)

Indication: Melanoma

Location: Texas Oncology-Austin Midtown

Phase: III

Title: Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2 View

Description: A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02)

Indication: Melanoma

Location: Texas Oncology-Austin Brain Tumor Center

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III

Title: Ph3 HIPEC with Cisplatin versus no HIPEC of Hyperthermic Ovarian Treatment Trial (HOTT) View

Description: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 HIPEC with Cisplatin versus no HIPEC of Hyperthermic Ovarian Treatment Trial (HOTT) View

Description: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)

Indication: Ovarian Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 HIPEC with Cisplatin versus no HIPEC of Hyperthermic Ovarian Treatment Trial (HOTT) View

Description: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: Ph3 HIPEC with Cisplatin versus no HIPEC of Hyperthermic Ovarian Treatment Trial (HOTT) View

Description: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: Ph3 HIPEC with Cisplatin versus no HIPEC of Hyperthermic Ovarian Treatment Trial (HOTT) View

Description: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) (GOG-3068/HOTT)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Austin Central

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-South Austin

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Austin North Suite 300

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Austin North Suite 120

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Austin North Next Oncology

Phase: III